Harmonization of molecular monitoring of CML therapy in Europe

Date

2009

Authors

Muller, M.
Cross, N.
Erben, P.
Schenk, T.
Hanfstein, B.
Ernst, T.
Hehlmann, R.
Branford, S.
Saglio, G.
Hochhaus, A.

Editors

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Journal article

Citation

Leukemia, 2009; 23(11):1957-1963

Statement of Responsibility

MC Muller, NCP Cross, P Erben, T Schenk, B Hanfstein, T Ernst, R Hehlmann, S Branford, G Saglio and A Hochhaus

Conference Name

Abstract

The high efficacy of the standard treatment of chronic myeloid leukemia (CML) with imatinib has prompted the need for accurate methods to monitor response at levels below the landmark of complete cytogenetic remission. Quantification of BCR–ABL transcripts has proven to be the most sensitive method available, and has shown prognostic impact with regard to progression-free survival. Until recently, variations in methods used to quantify BCR–ABL made it difficult to compare results between laboratories. An international program is now underway to harmonize the reporting of results according to an international scale (IS). In this review, we consider the background to the IS and the progress that has been made to date, with a particular focus on ongoing harmonization efforts in Europe. We provide recommendations for the propagation of the IS by national or regional laboratory networks.

School/Discipline

Dissertation Note

Provenance

Description

Access Status

Rights

© 2009 Macmillan Publishers Limited. All rights reserved

License

Grant ID

Call number

Persistent link to this record